Certara (CERT) announced a partnership with NVIDIA to integrate the BioNeMo Agent Toolkit into its open AI platform for biosimulation and regulatory workflows in drug development. At a share price of $6.79, Certara has seen a 30-day share price return of 30.58%, although the year to date share price return is down 22.31% and the 1-year total shareholder return is down 39.05%. The most followed narrative implies a fair value of $7.48, pointing to modest upside. The SWS DCF model points to Certara being 50.7% below an estimated fair value of $13.78, yet the market is pricing the stock at a P/S of 2.5x, which is higher than both the US Healthcare Services industry at 2.5x and the peer average at 2.3x, and above a fair ratio of 1.5x. The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning.